Company Overview
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Recent Developments
- Dec 2025 Revenue of $62.90M (+699.0% YoY); net profit $-204.63M.
- Trailing 12 Months Year-on-year growth — revenue +555.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 555.60% |
Stock Price Performance
| 1 Year: | +160.92% |
| 6 Months: | +48.37% |
| 3 Months: | +41.29% |
| 1 Month: | +11.46% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)53.80 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 28.6% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NUVB Nuvation Bio Inc. R2KR3KPHARMA | 6.81 | -15.48 | $2.38B | 0.00% | -41.57% | -47.81% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 1.44M | 727.00K | 3.08M | 4.83M | 13.12M | 83.23M | 31.69M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 88.00K | -788.00K | 990.00K | 2.26M | 9.77M | - | - |
| Operating Income | -9.22M | -9.02M | -11.55M | -20.48M | -20.43M | -22.79M | -28.19M | -37.87M | -29.34M | -26.52M | -26.13M | -26.34M | -20.20M | -470.38M | -48.10M | -59.00M | -63.59M | -56.43M | 3.88M | -51.04M |
| Net Income | -8.75M | -8.60M | -11.03M | -20.40M | -19.33M | -21.98M | -21.29M | -34.86M | -27.20M | -21.73M | -20.64M | -19.65M | -14.79M | -462.49M | -41.21M | -53.24M | -59.01M | -55.79M | 5.40M | -62.84M |
| Diluted EPS | - | - | - | - | -0.09 | -0.11 | -0.10 | -0.16 | -0.12 | -0.10 | -0.09 | -0.09 | -0.07 | -1.89 | -0.15 | -0.16 | -0.17 | -0.16 | 0.01 | -0.18 |
| R&D Expense | 7.29M | 7.34M | 8.63M | 15.88M | 14.03M | 17.12M | 20.73M | 28.92M | 21.29M | 18.79M | 18.59M | 18.56M | 12.84M | 29.25M | 27.73M | 24.60M | 27.36M | 28.85M | 35.05M | 30.66M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | 0 | 7.87M | 62.90M |
| Gross Profit | - | - | - | 0 | 795.00K | - |
| Operating Income | -43.55M | -93.32M | -119.73M | -99.82M | -592.63M | -213.06M |
| Net Income | -41.66M | -86.85M | -104.20M | -75.80M | -567.94M | -204.63M |
| Diluted EPS | - | -0.44 | -0.48 | -0.35 | -2.11 | -0.60 |
| R&D Expense | 32.60M | 69.04M | 87.81M | 71.29M | 99.12M | 115.11M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Apr 2020 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 221.79M | - | 672.14M | 621.48M | 540.63M | 594.82M |
| Current Assets | - | - | - | - | 667.32M | 616.43M | 526.25M | 571.52M |
| Cash & Equivalents | - | 0 | 29.75M | - | 101.10M | 42.65M | 35.72M | 164.09M |
| Inventory | - | - | - | - | - | - | 0 | 11.41M |
| Receivables | - | - | - | - | - | 0 | 12.72M | 16.08M |
| Total Liabilities | - | - | 6.71M | - | 17.07M | 16.36M | 76.84M | 289.11M |
| Current Liabilities | - | - | 6.55M | - | 13.16M | 13.97M | 58.24M | 82.23M |
| Long Term Debt | - | - | - | - | - | - | - | 47.21M |
| Total Debt | - | - | - | - | 4.26M | 4.01M | 8.91M | 57.35M |
| Total Equity | 117.75M | 0 | 215.08M | - | 655.08M | 605.12M | 463.79M | 305.72M |
| Shares Outstanding | - | - | - | - | 218.63M | 219.05M | 337.84M | 346.50M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -36.53M | -68.19M | -96.11M | -68.00M | -130.41M | -173.43M |
| Investing Cash Flow | -70.32M | -454.67M | 63.46M | 8.92M | 122.70M | 99.52M |
| Financing Cash Flow | 133.13M | 625.53M | 1.33M | 628.00K | 331.00K | 202.53M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 10.1% | - |
| Operating Margin % | - | - | - | - | -7,527.3% | -338.7% |
| Net Margin % | - | - | - | - | -7,213.8% | -325.3% |
| ROE % | -19.4% | - | -15.9% | -12.5% | -122.5% | -66.9% |
| ROCE % | -20.2% | - | -18.2% | -16.4% | -122.9% | -41.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.88% | 52.23M | $347.85M |
| 2 | Blackrock Inc. | 7.87% | 27.63M | $184.02M |
| 3 | Decheng Capital LLC | 7.39% | 25.95M | $172.86M |
| 4 | Vanguard Capital Management LLC | 3.39% | 11.92M | $79.38M |
| 5 | Omega Fund Management, Llc | 2.30% | 8.08M | $53.82M |
| 6 | Laurion Capital Management, LP | 2.23% | 7.82M | $52.08M |
| 7 | State Street Corporation | 2.10% | 7.37M | $49.09M |
| 8 | Geode Capital Management, LLC | 1.78% | 6.24M | $41.59M |
| 9 | Duquesne Family Office Llc | 1.29% | 4.54M | $30.24M |
| 10 | American Century Companies Inc | 1.28% | 4.50M | $29.97M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NUVB
Can Nuvation Bio Inc (NUVB) Stock Soar 150% From Current Level? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxOcFBVVi1URkdvVmh0eGRWWUNYX1puemJTWnk4dEVza1JFS0xFREZnOEEwSUpYYnM5bkM3RElzVzRvb1NwVFdsQTlERzVNQ2QweldrM1hpaklrSVlsbGdNZFBBZG9XbTJCYlZINXRzS1pBMDdnRDdPTWxJeFdFclZBSHVaa2dCQXgtYXl3M3…
Understanding the Setup: (NUVB) and Scalable Risk - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxQaEMtT3dOM1dLMm5nMkltSXBReUdmQ00xbEI2LVVyaFVHZ1QxaTUzaVc2X0RTOExhVGZXZW1lNTl4Y05PNXlOdHR3QUNYdWtMODFvMk52UzRMRXVlb3N0eDlsYkhSRFhVQkYyT1N3Y1RTUnV1RlhqbnVfSEFmWEg1cF9uLUtXbUJiLUZoa3…
Nuvation Bio (NUVB) Wins FDA Fast Track Status, Is The Stock Still Undervalued? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxPc20xNlgzZlE4RXYzM2d3bTFNWmhBOTd6d3BYS0F2ODBpWDJzNGg0VkhadXNybkU3UFJDaTFSYWFrWjBiME9aN19ZbDJ2eU03WHkyTUVGWlRJb3F3aVJvWDRobHZJY2U3NXA3WE45clY5WlRVVnpwVF9kMl9TNFFGU0tmd3RITWdnWWFMMm…
Nuvation Bio (NUVB) CSO sells 100K shares at $7.09 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxOUUgzSUJfblpmc2xHdm1iYmRBM3NEVDF4cFBaVWI5LThiZmF1TkIyemU0X2lET3ZJX3gzRWxHcjFlX1JhU191Qi1BbVk0aWJPXzlRaE9TOG1hNFJTUWZQdVVWLVpFZ1BJSmZWNXFySXFzQ2xuSUxFUW1Xa3E2b1BUWnM0cktiR3g3M0dWel…
NUVB Stock Is Soaring Today — Why RBC Sees $3B Opportunity In Nuvation Bio's Brain Cancer Drug - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxPbmJQMnR2R3BkM0NhR0RGbi15aUlHaWJnYVpDS2ZETFpmZ2lCVjFQcmxzMFp1WHB5WDZGaW5MbXBVTjRDUDItQ19FRHYyYVVBazQ3alJVVEl1SXBnMzlHRlpCR2tPcjZiVlNxSFA3cUc0eGQwQTJjZDUzQmx2bHRQeFV0WEU3aGdBWl9yOT…
Cramer's lightning round: Nuvation Bio 'is a pure spec' - CNBC
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxPWVV2NlI0TU1WSU5yMUhlbUJPTzE3bURDaS1ia3lKWFQ0OUdGSXBxdlFnemxWMDZHc01pUEZwTXZISUtyVmQtSEY1YXgxQTAyNzBOLUcwX3N5OWw0STh5c0tid2ZHVm1CT0N5Z1lDVWVuRkdLT3NPcVVMZnNLTnM0cDNpTmRqLUptM3V6RE…
NUVB — Frequently Asked Questions
What is the current share price of Nuvation Bio Inc. (NUVB)?
As of 2026-09-07 16:24 PDT, Nuvation Bio Inc. (NUVB) trades at $6.81 on NYSE. Its 52-week range is $2.61 to $9.54.
What is the market capitalisation of NUVB?
Nuvation Bio Inc. (NUVB) has a market capitalisation of $2.38B on NYSE.
What is the P/E ratio of NUVB?
NUVB trades at a trailing price-to-earnings (P/E) ratio of -15.48. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 7.18.
What is the return on equity (ROE) of NUVB?
NUVB has a return on equity (ROE) of -47.81%. Its return on capital employed (ROCE) is -41.57%.
Is NUVB a good stock to buy?
This page provides a data-driven analysis of Nuvation Bio Inc. (NUVB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.